Discontinued Drugs – 2026
By Month & Product Name
The source links for the following discontinued products are as announced by the U.S. Food & Drug Administration (FDA)
after the manufacturer has notified the FDA of the discontinuation.
- 2mg/2mL (1mg/mL): 5-count single-dose vials (NDC #63323-970-02)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 7mg: 10-count single-dose vials (NDC #63323-358-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.5%: 1-count 3.5Gm tube (NDC #0023-6118-03)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg: 10-count single-dose ADD-Vantage® glass vials (NDC #0409-4350-03)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg:
- 20-count bottles (NDC #0378-0167-13)
- 100-count bottles (NDC #0378-0167-02)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Doxylamine Succinate/Pyridoxine Hydrochloride Delayed-Release Tablets – January 12, 2026
Viatris Inc. (labeled by Mylan)
Viatris Inc. (labeled by Mylan)
- 10mg/10mg: 100-count bottles (NDC #0378-4615-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2.5mg: 28-count unit-dose packages (NDC #49884-119-91)
- 5mg: 28-count unit-dose packages (NDC #49884-125-91)
- 7.5mg: 28-count unit-dose packages (NDC #49884-127-91)
- 10mg: 28-count unit-dose packages (NDC #49884-128-91)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 80mg:
- 30-count bottles (NDC #0781-8017-31)
- 100-count bottles (NDC #0781-8017-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg/mL: 1-count multi-dose vial (NDC #63323-469-01)
- 250mg/5ml (50mg/mL): 1-count multi-dose vial (NDC #63323-469-05)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 200mg: 100-count bottles (NDC #0093-2401-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 40mg/0.4mL: 2-count prefilled syringes (NDC #61314-473-64)
- 80mg/0.8mL:
- 3-count prefilled syringes for pediatric patients (NDC #61314-454-68)
- 3-count single-dose prefilled Sensoready® pens (NDC #61314-454-36)
- 80mg/0.8mL & 40mg/0.4mL Kit:
- 2-count single-dose prefilled syringes for pediatric patients (NDC #61314-531-64)
- 3-count single-dose prefilled Sensoready pens (NDC #61314-517-36)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 80mg: 30-count bottles (NDC #66758-211-31)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 5mg/10mL (0.5mg/mL): 10-count multi-dose vials (NDC #63323-413-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Photrexa® (riboflavin 5-phosphate) Cross-Linking Ophthalmic Solution Kit – January 20, 2026
Glaukos Corporation
Glaukos Corporation
- Kit: 1-count syringe of Photrexa® and 1-count syringe of Photrexa Viscus (NDC #25357-025-03)
Note: Product is stored under refrigeration.
Discontinuing manufacture of the product as of February 2026.
- 5mg: 100-count bottles (NDC #57664-655-88)
Expiry date of last distributed batch is January 2027.
- 10mg: 100-count bottles (NDC #57664-656-88)
Expiry date of last distributed batch is October 2026.
- 2.25Gm: 10-count single-dose vials (NDC #65219-434-20)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 500mg: 25-count vials per package (NDC #0006-3516-59)
To be discontinued in approximately mid-2026.
- 20mg/mL: 1-count 230mL bottle and 2-count oral dosing syringes per kit (NDC #49702-260-55)
The anticipated cease date for distribution of the product is approximately August 1, 2026.
- 500mg: 10-count single-dose ADD-Vantage® vials (NDC #0069-3150-83)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg:
- 100-count bottles (NDC #0591-5543-01)
- 1,000-count bottles (NDC #0591-5543-10)
- 300mg:
- 100-count bottles (NDC #0591-5544-01)
- 500-count bottles (NDC #0591-5544-05)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 10mg/10mL (1mg/mL): 1-count single-dose vial (NDC #50742-438-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 450mg/45mL (10mg/mL): 1-count multi-dose vial (NDC #50742-447-45)
- 600mg/60mL (10mg/mL): 1-count multi-dose vial (NDC #50742-448-60)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 1Gm: 10-count single-dose vials (NDC #63323-326-20)
- 2Gm: 10-count single-dose vials (NDC #63323-340-20)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 75mg: 100-count bottles (NDC #0009-0331-02)
- 150mg: 100-count bottles (NDC #0009-0225-02)
- 300mg: 100-count bottles (NDC #0009-0395-14)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 9,000mg/60mL (150mg/mL): 5-count bulk vial packages (NDC #0009-0728-09)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Clindamycin Palmitate Hydrochloride for Oral Solution (Pediatric) – February 27, 2026
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc.
- 75mg/5mL: 1-count 100mL bottle with 75mL of solution when reconstituted (NDC #53746-468-19)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg:
- 1-count single-dose vial (NDC #50742-430-01)
- 1-count single-dose vial (NDC #68001-573-41) labeled by BluePoint Laboratories
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 250mg/5mL (50mg/mL): 237mL bottles (NDC #65649-311-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 80mg/8mL (10mg/mL): 1-count multi-dose vial (NDC #50742-431-08)
- 160mg/16mL (10mg/mL): 1-count multi-dose vial (NDC #50742-463-16)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2.5mg: 9-count blister card (NDC #63481-025-09)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 40mg/2mL(20mg/mL): 1-count single-dose vial (NDC #50742-401-02)
- 100mg/5mL(20mg/mL): 1-count single-dose vial (NDC #50742-402-05)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 600mg/2mL (300mg/mL): 1-count multiple-dose vial (NDC #0009-0104-04)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 600mg: 60-count bottles (NDC #0071-0737-20)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg/10mL (5mg/mL): 1-count single-dose vial (NDC #63323-750-10)
- 100mg/20mL (5mg/mL): 1-count single-dose vial (NDC #63323-750-20)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg:
- 30-count bottles (NDC #50458-290-04)
- 30-count unit-dose blister packs (NDC #50458-290-01)
- 30-count bottles (NDC #10147-1700-3) labeled by Patriot Pharmaceuticals, LLC
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Clindamycin Palmitate Hydrochloride Oral Solution (Pediatric) – March 26, 2026
Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc.
- 75mg/5mL: 1-count 100mL bottle with 75mL of solution when reconstituted (NDC #53746-468-19)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 5mg/5mL (1mg/mL): 2-count plastic ampules per carton (NDC #55513-813-28)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 5mg: 60-count bottles (NDC #55513-800-60)
- 7.5mg: 60-count bottles (NDC #55513-810-60)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 4%: 6-count single-use prefilled applicators (NDC #0023-6150-04)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 7.5%: 60Gm pump bottle (NDC #69238-1627-6)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2.5mg: 28-count blister packs (NDC #0093-7766-24)
- 5mg: 28-count blister packs (NDC #0093-7767-24)
- 7.5mg: 28-count blister packs (NDC #0093-7768-24)
- 10mg: 28-count blister packs (NDC #0093-7769-24)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 600mg/2mL (300mg/mL): 10-count vials (NDC #39822-0350-2)
- 3Gm/10mL (300mg/mL): 10-count vials (NDC #39822-0355-6)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2.5mg:
- 30-count bottles (NDC #13668-353-30)
- 90-count bottles (NDC #13668-353-90)
- 100-count bottles (NDC #13668-353-01)
- 500-count bottles (NDC #13668-353-05)
- 5mg:
- 30-count bottles (NDC #13668-354-30)
- 90-count bottles (NDC #13668-354-90)
- 100-count bottles (NDC #13668-354-01)
- 500-count bottles (NDC #13668-354-05)
- 10mg:
- 30-count bottles (NDC #13668-355-30)
- 90-count bottles (NDC #13668-355-90)
- 100-count bottles (NDC #13668-355-01)
- 500-count bottles (NDC #13668-355-05)
- 20mg:
- 30-count bottles (NDC #13668-356-30)
- 90-count bottles (NDC #13668-356-90)
- 100-count bottles (NDC #13668-356-01)
- 500-count bottles (NDC #13668-356-05)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 300mg/3mL:
- 1-count single-dose vial (NDC #39822-3050-1)
- 10-count single-dose vials (NDC #39822-3050-2)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 24mg/1.2mL (20mg/mL): 1-count single-dose vial (NDC #65219-284-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 8mg:
- 30-count bottles (NDC #64764-805-30)
Product is expected to be available through June 2027.
- 100-count bottles (NDC #64764-805-10)
Product is expected to be available through February 2027.
- 200mg: 240-count bottles (NDC #72607-100-00)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Vuity™ (pilocarpine hydrochloride) Ophthalmic Solution – March 24, 2026
AbbVie Inc. (distributed by Allergan)
AbbVie Inc. (distributed by Allergan)
- 1.5mL: 1.25% (12.5mg/mL)
- 1-count professional sample bottle (NDC #0074-7098-05)
- 2.5mL: 1.25% (12.5mg/mL)
- 1-count bottle per box (NDC #0074-7098-01)
- 1-count bottle per carton (NDC #0074-7098-04)
- 3-count bottles per box (NDC #0074-7098-03)
- 5mL: 1.25% (12.5mg/mL)
- 1-count bottle per carton (NDC #0074-7098-06)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25mg: 60-count bottles (NDC #70370-5025-1)
Neurocrine is discontinuing only the 25mg soft gel capsule dose strength (NDC #70370-5025-01). The 50mg & 100mg soft gel capsule dose strengths (NDC #70370-5050-1 & #70370-5100-1), & 50mg/mL oral solution (NDC #70370-5250-1) will continue to be marketed.
- 100mcg/mL: 25-count cartons (NDC #16729-239-93)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 1.25mg: Single-dose kit (NDC #0006-3066-03)
To be discontinued in approximately November 2026.
Etravirine Tablets – April 28, 2026
Patriot Pharmaceuticals, LLC (a wholly owned subsidiary of Janssen Pharmaceuticals)
Patriot Pharmaceuticals, LLC (a wholly owned subsidiary of Janssen Pharmaceuticals)
- 100mg: 120-count bottles (NDC #10147-0570-1)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 150mg/5mL: 1-count single-dose vial (NDC #63323-972-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 20mg/2mL (10mg/1mL): 25-count single-dose vials per carton (NDC #25021-311-02)
- 40mg/4mL (10mg/1mL): 25-count single-dose vials per carton (NDC #25021-311-04)
- 100mg/10mL (10mg/1mL): 25-count single-dose vials per carton (NDC #25021-311-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 75mg: 21-count bottles (NDC #0069-0187-21)
- 100mg: 21-count bottles (NDC #0069-0188-21)
Note: Tablets will continue to be manufactured.
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Icosapent Ethyl Capsules – April 1, 2026
Apotex Corp. (in partnership with Golden State Medical Supply, Inc.)
Apotex Corp. (in partnership with Golden State Medical Supply, Inc.)
- 1Gm: 120-count bottles (NDC #60429-005-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
INTELENCE® (etravirine) Tablets – April 28, 2026
Janssen Products LP (now known as Johnson & Johnson Innovative Medicine – United States)
Janssen Products LP (now known as Johnson & Johnson Innovative Medicine – United States)
- 100mg: 120-count bottles (NDC #59676-570-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Ketorolac Tromethamine Tablets – April 20, 2026
Viatris, Inc. (labeled by Mylan Pharmaceuticals, Inc.)
Viatris, Inc. (labeled by Mylan Pharmaceuticals, Inc.)
- 10mg: 100-count bottles (NDC #0378-1134-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25mg: 30-count bottles (NDC #49884-561-11)
- 50mg: 30-count bottles (NDC #49884-562-11)
- 100mg: 30-count bottles (NDC #49884-563-11)
- 200mg: 30-count bottles (NDC #49884-564-11)
- 250mg: 30-count bottles (NDC #49884-604-11)
- 300mg: 30-count bottles (NDC #49884-605-11)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25mg/5mL: 250mL glass bottles (NDC #69238-2512-9)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.04%: 30Gm tubes (NDC #58914-301-80)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 600mg: 1-count vial (NDC #0068-0597-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2mg: 30-count bottles (NDC #0093-5030-56)
- 4mg: 30-count bottles (NDC #0093-5031-56)
- 12mg: 30-count bottles (NDC #0093-8072-56)
- 16mg: 30-count bottles (NDC #0093-8076-56)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 300mg:
- 30-count bottles (NDC #64380-844-04)
- 100-count bottles (NDC #64380-844-06)
- 500-count bottles (NDC #64380-844-07)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 250mg: 30-count bottles (NDC #0069-4061-01)
- 500mg: 30-count bottles (NDC #0069-3070-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg: 60-count bottles (NDC #61958-1701-1)
- 150mg: 60-count bottles (NDC #61958-1702-1)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25Gm activated charcoal/48Gm sorbitol:
- 120mL tube (NDC #0574-0520-74)
- 240mL tube (NDC #0574-0520-76)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25Gm activated charcoal:
- 72mL tube (NDC #0574-0521-25)
- 120mL tube (NDC #0574-0521-74)
- 240mL tube (NDC #0574-0521-76)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg: 1-count single-dose vial with diluent (NDC #50242-085-27)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.25%:
- 75mg/30mL (2.5mg/mL): 1-count 30mL single-dose vial (NDC #71288-722-32)
- 125mg/50mL (2.5mg/mL): 1-count 50mL multi-dose vial (NDC #71288-723-52)
- 0.5%:
- 150mg/30mL (5mg/mL): 1-count 30mL single-dose vial (NDC #71288-725-32)
- 150mg/30mL (5mg/mL): 1-count 30mL single-dose vial (NDC #71288-725-32)
- 0.75%:
- 225mg/30mL (7.5mg/mL): 1-count 30mL single-dose vial (NDC #71288-728-32)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 20mg/10mL (2mg/mL): 10-count multi-dose vials (NDC #0409-1208-01)
- 200mg/20mL (10mg/mL): 10-count single-dose vials (NDC #0409-1103-01)
Supply is expected to be exhausted in late June 2026.
- 1mL/mL: 10-count 5mL single-dose vials per pack (NDC #16729-710-45)
Accord is transitioning to the 5-count pack configuration (NDC #16729-710-53).
- 1.0%:
- 5mL bottle (NDC #69489-721-05)
- 30mL bottle (NDC #69489-721-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2.5mmol/5mL (0.5mmol/mL): 10-count single-dose vials per tray (NDC #65219-080-05)
- 5mmol/10mL (0.5mmol/mL): 10-count single-dose vials per tray (NDC #65219-082-10)
- 7.5mmol/15mL (0.5mmol/mL): 10-count single-dose vials per tray (NDC #65219-084-15)
- 10mmol/20mL (0.5mmol/mL): 10-count single-dose vials per tray (NDC #65219-086-20)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 30mg/3mL (10mg/mL):
- 1-count prefilled single-dose syringe (NDC #63323-574-86)
- 3-count prefilled single-dose syringes (NDC #63323-574-93)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg/2.5mL: 10-count single-dose vials per carton (NDC #67457-957-99)
A business decision has been made to discontinue the 2.5mL presentation only. All other presentations remain available.
- 18mg/3mL (6mg/mL): 5-count prefilled pens per carton (NDC #0480-7250-46)
Note: Product is stored under refrigeration.
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Sulconazole Nitrate Solution – May 8, 2026
JG Pharma, Inc. (a wholly owned subsidiary of Journey Medical Corporation)
JG Pharma, Inc. (a wholly owned subsidiary of Journey Medical Corporation)
- 1.0%: 30mL bottle (NDC #72143-321-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 10mg: 30-count bottles (NDC #0088-2160-30)
- 20mg: 30-count bottles (NDC #0088-2161-30)
- 100mg: 3-count blister packs (NDC #0088-2162-33)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg/5mL (10mg/mL): 1-count multiple-dose vial (NDC #60505-6282-1)
- 150mg/15mL (10mg/mL): 1-count multiple-dose vial (NDC #60505-6282-3)
- 450mg/45mL (10mg/mL): 1-count multiple-dose vial (NDC #60505-6282-6)
- 600mg/60mL (10mg/mL): 1-count multiple-dose vial (NDC #60505-6282-7)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Cleocin Phosphate® (clindamycin) Injection – June 1, 2026
Pfizer Hospital (a subsidiary of Pfizer Inc.)
Pfizer Hospital (a subsidiary of Pfizer Inc.)
- 300mg/2mL (150mg/mL): Carton of 25-count single-dose vials (NDC #0009-0870-26)
- 600mg/4mL (150mg/mL): Carton of 25-count single-dose vials (NDC #0009-0775-26)
- 900mg/6mL (150mg/mL): Carton of 25-count single-dose vials (NDC #0009-0902-18)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Cleocin Phosphate® (clindamycin) Injection with NovaPlus™ Label – June 1, 2026
Pharmacia & Upjohn Company LLC
Pharmacia & Upjohn Company LLC
- 300mg/2mL (150mg/mL): 25-count single-dose vials in NovaPlus™ carton (NDC #0009-3051-02)
- 600mg/4mL (150mg/mL): 25-count single-dose vials in NovaPlus carton (NDC #0009-4073-04)
- 900mg/6mL (150mg/mL): 25-count single-dose vials in NovaPlus carton (NDC #0009-5095-06)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 200mcg/50mL (4mg/mL): 20-count single-dose bottles per carton (NDC #71225-126-05)
- 400mcg/100mL (4mg/mL): 30-count bottles (NDC #0088-2161-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 14mg/10mg: 30-count bottles (NDC #69238-1248-3)
- 28mg/10mg: 30-count bottles (NDC #69238-1247-3)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 200mg: 30-count bottles (NDC #61958-0601-1)
Product expected to be available until March 2027.
- 10mg/mL: 170mL bottles (NDC #61958-0602-1)
Product expected to be available until March 2027.
- 10mg: 30-count bottles (NDC #0955-1735-30)
- 20mg: 30-count bottles (NDC #0955-1737-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25mg: 120-count bottles (NDC #0069-0227-03)
Lorbrena® 25mg in 30-count bottles (NDC #0069-0227-01) will continue to be manufactured.
- 15mg: 30-count bottles (NDC #0069-0197-30)
- 30mg: 30-count bottles (NDC #0069-1198-30)
- 45mg: 30-count bottles (NDC #0069-2299-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 45mcg/21mcg: 120-metered actuations per canister (NDC #0173-0715-22)
- 115mcg/21mcg: 120-metered actuations per canister (NDC #0173-0716-22)
- 230mcg/21mcg: 120-metered actuations per canister (NDC #0173-0717-22)
The anticipated date that GSK will cease distribution of the above presentation is approximately December 31, 2026. The 120-dose presentation of this product will still be available.
- 300mg: 12-count unit-dose cartons (NDC #0574-7034-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 16.2mg/30mg:
- 4-count unit-dose cartons (NDC #0574-7045-04)
- 12-count unit-dose cartons (NDC #0574-7045-12)
- 16.2mg/60mg:
- 4-count unit-dose cartons (NDC #0574-7040-04)
- 12-count unit-dose cartons (NDC #0574-7040-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 240mL/240mL: 6-count cartons (NDC #0781-6172-86)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg: 120-count bottles (NDC #0591-4550-22)
- 200mg: 60-count bottles (NDC #0591-4575-60)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.2mg/mL:
- 25-count 1mL single-dose vials (NDC #63323-578-01)
- RFID-tagged 25-count 1mL single-dose vials (NDC #65219-801-01)
- 0.4mg/2mL (0.2mg/mL): 25-count 2mL single-dose vials (NDC #63323-578-02)
- 1mg/5mL (0.2mg/mL): 25-count 5mL multi-dose vials (NDC #63323-578-05)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25mg: 12-count unit-dose cartons (NDC #0574-7090-12)
- 30mg: 12-count unit-dose cartons (NDC #0574-7093-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 3mg: 6-count unit-dose cartons (NDC #0574-7224-06)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg/25mg:
- 60-count bottles (NDC #0074-0522-60)
- 60-count bottles (NDC #0074-3008-60)
- 200mg/50mg:
- 120-count bottles (NDC #0074-6799-22)
- 120-count bottles (NDC #0074-4014-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 5mg: 12-count unit-dose cartons (NDC #0574-7110-12)
- 10mg: 12-count unit-dose cartons (NDC #0574-7112-12)
- 20mg: 12-count unit-dose cartons (NDC #0574-7114-12)
- 30mg: 12-count unit-dose cartons (NDC #0574-7116-12)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25%: 1-count 15mL bottle (NDC #0574-0601-15)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg: 30-count single-use foil packets (NDC #0074-3399-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg: 30-count bottles (NDC #0074-2340-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 100mg: 30-count bottles (NDC #0074-2340-30)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 200mg/10mL (20mg/mL): 25-count 10mL multi-dose vials (NDC #63323-943-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 80mg/2mL (40mg/mL): 25-count multi-dose glass Fliptop vials (NDC #0409-3578-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.004% (0.04mg/mL):
- 1-count 2.5mL bottle (NDC #0378-9651-32)
- 1-count 5mL bottle (NDC #0378-9651-50)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Treanda® (bendamustine HCl) for Injection – July 23, 2026
Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceuticals)
Cephalon, LLC (a wholly owned subsidiary of Teva Pharmaceuticals)
- 25mg: 1-count 8mL single-dose vial (NDC #63459-390-08)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Cardioplegic (potassium chloride/sodium chloride/calcium chloride/magnesium chloride) Solution – August 31, 2026
Fresenius Kabi USA, LLC
Fresenius Kabi USA, LLC
- 119.3mg/643mg/17.6mg/325.3mg per 100mL: 10-count single-dose 1,000mL freeflex® bags (NDC #65219-258-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg:
- 60-count bottles (NDC #0228-2550-06)
- 100-count bottles (NDC #0228-2550-11)
- 1,000-count bottles (NDC #0228-2550-96)
- 75mg:
- 60-count bottles (NDC #0228-2551-06)
- 100-count bottles (NDC #0228-2551-11)
- 1,000-count bottles (NDC #0228-2551-96)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 250mg/5mL (50mg/mL): 2-count single-dose prefilled syringes (NDC #63323-715-05)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 1.25mg: 50-count bottles (NDC #0093-9477-53)
- 2.5mg: 100-count bottles (NDC #0093-9433-01)
- 5mg:
- 100-count bottles (NDC #0093-9364-01)
- 1,000-count bottles (NDC #0093-9364-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.375Gm: 120-count bottles (NDC #0378-1375-78)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 25mg:
- 100-count bottles (NDC #45963-709-11)
- 1,000-count bottles (NDC #45963-709-96)
- 50mg:
- 100-count bottles (NDC #45963-676-11)
- 1,000-count bottles (NDC #45963-676-96)
- 100mg:
- 100-count bottles (NDC #45963-677-11)
- 1,000-count bottles (NDC #45963-677-96)
- 200mg: 100-count bottles (NDC #45963-678-11)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Plenvu® (polyethylene glycol 3350/sodium ascorbate/sodium sulfate/ascorbic acid/sodium chloride/potassium chloride) Oral Solution Kit – August 13, 2026
Salix Pharmaceuticals, Inc.
Salix Pharmaceuticals, Inc.
- 140Gm/48.11Gm/9Gm/7.54Gm/5.2Gm/2.2Gm:
Kit contains 1-count pouch of Dose 1 and 2-count pouches of Dose 2 (NDC #65649-400-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 2.5mg: 100-count bottles (NDC #0009-0065-01)
Withdrawal from sale is expected in early October 2026.
- 10mg: 100-count bottles (NDC #0009-0051-01)
Withdrawal from sale is expected in September 2026.
- 18mg/3mL (6mg/mL): 5-count prefilled pens (NDC #0169-2800-15)
Product will be available until discontinuation in January 2027.
- 2.5mg: 14-count blister pack (NDC #15054-0025-1)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 10mg/10mL (1mg/mL): 10-count single-dose vials (NDC #63323-637-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 10mg/5mL (2mg/mL): 10-count single-dose vials (NDC #0409-1098-02)
Supply is expected to exhaust in November 2026.
- 20mg/10mL (2mg/mL): 10-count multi-dose vials (NDC #0409-1208-01)
Supply has been fully depleted.
- 200mg/20mL (10mg/mL): 10-count single-dose vials (NDC #0409-1103-01)
Supply has been fully depleted.
- 100 units/mL: 5-count 3mL prefilled pens (NDC #0002-7752-05)
Distribution is projected to end in June 2027.
Humalog® Mix75/25™ (insulin lispro protamine/insulin lispro) KwikPen® Injectable Suspension – September 1, 2026
Eli Lilly and Company
Eli Lilly and Company
- 100 units/mL: 5-count 3mL single-patient-use prefilled pens (NDC #0002-8233-05)
Distribution is projected to end in June 2027.
- 50mg kit: 1-count single-use vial with 50mg of melphalan and 1-count 10mL vial of sterile diluent (NDC #63323-760-20)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 50mg (10mg/mL): 10-count single-dose vials (NDC #42023-229-10)
- 100mg (20mg/mL): 10-count single-dose vials (NDC #42023-230-10)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Pentasa® (mesalamine) Extended-Release Capsules – September 16, 2026
Takeda Pharmaceuticals America, Inc.
Takeda Pharmaceuticals America, Inc.
- 250mg: 240-count bottles (NDC #54092-189-81)
- 500mg: 120-count bottles (NDC #54092-191-12)
Both products are anticipated to be available until December 31, 2027.
- 1.1Gm/mL:
- 1-count 25mL bottle (NDC #75987-050-06)
- 4-count 25mL bottles (NDC #75987-050-07)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 500mg/500mg/250mg per vial: 25-count single-dose glass vials (NDC #0006-3856-02)
To be discontinued on or near late September 2026.
- 100 units/mL: 5-count 3mL prefilled pens (NDC #0002-8980-05)
Distribution is projected to end in June 2027.
- 4.6mg/24 hours: 30-count patches (NDC #0378-9070-93)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 3mg: 20-count packages (NDC #0006-0032-01)
Product will be discontinued on October 31, 2026.
Xarelto® (rivaroxaban) for Oral Suspension – September 18, 2026
Janssen Pharmaceuticals, Inc. (labeled by Johnson & Johnson)
Janssen Pharmaceuticals, Inc. (labeled by Johnson & Johnson)
- 1mg/mL (when reconstituted): 1-count 155mg bottle with 2 oral dosing syringes (NDC #50458-575-01)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
- 0.05%:
- 15Gm tube (NDC #0093-0264-15)
- 30Gm tube (NDC #0093-0264-30)
- 60Gm tube (NDC #0093-0264-92)
Date of expected product on-hand unavailability is unknown, other than above announcement date.
Content coming soon….
Content coming soon….